<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">IRON DEXTRAN</span><br/>(i'ern dek'stran)<br/><span class="topboxtradename">Dexferrum, </span><span class="topboxtradename">Imfed, </span><span class="topboxtradename">Imferon<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">iron preparation</span><br/><b>Prototype: </b>Ferrous sulfate<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg/mL</p>
<h1><a name="action">Actions</a></h1>
<p>A dark brown, slightly viscous liquid complex of ferric hydroxide with dextran in 0.9% NaCl solution for injection.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reticuloendothelial cells of liver, spleen, and bone marrow dissociate iron from iron dextran complex. The released ferric
         ion combines with transferrin and is transported to bone marrow, where it is incorporated into hemoglobin.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Only in patients with clearly established iron deficiency anemia when oral administration of iron is unsatisfactory or impossible.
         Each milliliter of iron dextran contains 50 mg elemental iron.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to the product; all anemias except iron-deficiency anemia. Safe use during pregnancy (category C) is not
         established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation; rheumatoid arthritis, ankylosing spondylitis; impaired hepatic function; history of allergies or asthma.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Iron Deficiency</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/IV</span> Dose is individualized and determined from a table of correlations between patient's weight and hemoglobin (see package insert);
               do not administer more than 100 mg (2 mL) of iron dextran within 24 h<br/><span class="rdage">Child:</span> <span class="rdroute">IM/IV</span>
<i> no more than 0.5 mL (25 mg)/d; <i>510 kg,</i> no more than 1 mL (50 mg)/d; <i>&gt;10 kg,</i> no more than 2 mL (100 mg)/d<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p>
         			Note: The multiple-dose vial is used <small>ONLY</small> for IM injections. It is not suitable for IV use because it contains a preservative (phenol).
         		
      </p><span class="adminroutetype">Test Dose</span><br/><ul>
<li>Give a test dose of 0.5 mL over a 5 min period before the first IM or IV therapeutic dose to observe patient's response to
            the drug. Have epinephrine (0.5 mL of a 1:1000 solution) immediately available for hypersensitivity emergency.
         </li>
<li>
            				Note: Although anaphylactic reactions (see Appendix F) usually occur within a few minutes after injection, it is recommended that
            1 h or more elapse before remainder of initial dose is given following test dose.
            			
         </li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Use the multiple-dose vial <small>ONLY</small> for IM injections. It is not suitable for IV use because it contains a preservative (phenol).
         </li>
<li>Give injection only into the muscle mass in upper outer quadrant of buttock (never in the upper arm). In small child, use
            the lateral thigh. Use a 2- or 3-inch, 19- or 20-gauge needle. The Z-track technique is recommended. Use one needle to withdraw
            drug from container and another needle for injection.
         </li>
<li>
            				Note: If patient is receiving IM in standing position, patient should be bearing weight on the leg opposite the injection site;
            if in bed, patient should be in the lateral position with injection site uppermost.
            			
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Ensure that <small>ONLY</small> the vial for IV use is selected.
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> If the IV injection does not exceed 100 mg, it is administered undiluted.  <span class="methodtype">IV Infusion:</span> Dilute in 2501000 mL of NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give 50 mg (1 mL) or fraction thereof over 60 sec.   <span class="methodtype">IV Infusion:</span> Give test dose of 25 mg (0.5 mL) over 5 min. If no adverse reactions occur, infuse remainder over 18 h.  
               </p>
<ul>
<li>After infusion is completed, flush vein with 10 mL of NS.</li>
<li>Have patient remain in bed for at least 30 min after IV administration to prevent orthostatic hypotension.</li>
<li>Monitor BP and pulse.</li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Store below 30° C (86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity (urticaria, skin rash, allergic purpura, pruritus, fever, chills, dyspnea, arthralgia, myalgia; <span class="speceff-life">anaphylaxis</span>). <span class="typehead">CNS:</span> Headache, shivering, transient paresthesias, syncope, dizziness, <span class="speceff-life">coma</span>, seizures. <span class="typehead">CV:</span>
<span class="speceff-common">Peripheral vascular flushing (rapid IV), hypotension,</span> precordial pain or pressure sensation, tachycardia, <span class="speceff-life">fatal cardiac arrhythmias, circulatory collapse</span>. <span class="typehead">GI:</span> Nausea, vomiting, transient loss of taste perception, metallic taste, diarrhea, melena, abdominal pain, hemorrhagic gastritis,
      intestinal necrosis, hepatic damage. <span class="typehead">Skin:</span> Sterile abscess and brown skin discoloration (IM site), local phlebitis (IV site), lymphadenopathy, <span class="speceff-common">pain at IM injection site</span>. <span class="typehead">Metabolic:</span> Hemosiderosis, metabolic acidosis, hyperglycemia, reactivation of quiescent rheumatoid arthritis, exogenous hemosiderosis. <span class="typehead">Hematologic:</span> Bleeding disorder with severe toxicity. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Falsely elevated <span class="alt">serum bilirubin</span> and falsely decreased <span class="alt">serum calcium</span> values may occur. Large doses of iron dextran may impart a brown color to serum drawn 4 h after iron administration. <span class="alt">Bone scans</span> involving Tc-99m diphosphonate have shown dense areas of activity along contour of iliac crest 16 d after IM injections
         of iron dextran.
      </p>
<h1><a name="interactions">Interactions</a></h1>May decrease absorption of oral <b>iron,</b>
<b>chloramphenicol</b> may decrease effectiveness of iron, a toxic complex may form with <b>dimercaprol.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 60% absorbed from IM site by 3 d; 90% absorbed by 13 wk. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in reticuloendothelial system. <span class="typehead">Half-Life:</span> 6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness: Anticipated response to parenteral iron therapy is an average weekly hemoglobin rise
            of about 1 g/d. Peak levels are generally reached in about 48 wk.
         </li>
<li>
            							Note: Systemic reactions may occur over 24 h after parenteral iron has been administered. Large IV doses are associated with increased
            frequency of adverse effects.
            						
         </li>
<li>Lab tests: Periodic determinations of Hgb and Hct, and reticulocyte count should be made.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not take oral iron preparations when receiving iron injections.</li>
<li>Eat foods high in iron and vitamin C.</li>
<li>Notify physician of any of the following: backache or muscle ache, chills, dizziness, fever, headache, nausea or vomiting,
            paresthesias, pain or redness at injection site, skin rash or hives, or difficulty breathing.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>